(Enhanced,1)
(Because,3)
(healing,1)
(greater,2)
(distances,1)
(maintained,1)
(intervals,3)
(b-carotene,3)
(3-4,1)
(order,1)
(neuropathic,2)
(requiring,1)
(evaluating,1)
(gap,1)
(structurally,1)
(accomplished,1)
(parent,2)
(minimum,1)
(MAPK/ERK,1)
(gut,2)
(Aims,1)
(Nine,1)
(triple,4)
(inhibitor,7)
(Ras/MAPK,1)
(IR-B,2)
(histology,2)
(coping,1)
(records,1)
(urgently,1)
(Western,1)
(a.u.,2)
(2005-2017,1)
(plus,2)
(methylation,3)
(heritability,1)
(fee-for-service,1)
(cohort;,1)
(completing,1)
(1.45,1)
(fibroblastic-to-epithelial,1)
(assessment,4)
(pathogenesis,6)
(aims,2)
(recognized,1)
(multigene,1)
(31,2)
(0.004,2)
(complexity,1)
(symptoms,3)
(thus,4)
('information',1)
(excluded,1)
(self-reports,1)
(21-,1)
(pursue,1)
(nonlinear,1)
(SNPs,12)
(cancer-related,8)
(US,3)
(According,2)
(perforator,1)
(reverse,2)
(found,15)
(affects,2)
(dehydrogenase,1)
(cohorts,1)
(associated,32)
(apoptosis-promoting,1)
(pipeline,1)
(certain,2)
(extranuclear,1)
(MicroRNAs,1)
(humans,1)
(defects,1)
(underutilized,1)
(wavelet,2)
(biochemical,1)
(voxel,3)
(emotional,1)
(methods,9)
(acquired,1)
(Ca,1)
(aspiration,1)
(unresected,2)
(rs10941679,1)
(interference,2)
(BCL-X,1)
(histopathology,1)
(synthesized,1)
(DWI,1)
(axillary,3)
(resource,1)
(invadopodia,5)
(giving,1)
(RT,1)
(utilization,2)
(semiconductors,1)
(resection,1)
(cell-targeting,1)
(letrozole,1)
(develops,2)
(intergenic,1)
(RESULTS,4)
(remarkable,1)
(need,2)
(b-cryptoxanthin,1)
(GPR30,3)
(focuses,1)
(families,11)
(comparing,1)
(acquire,1)
(whole-exome,1)
(transtuzumab,1)
(behavior,3)
(AI-based,3)
(skills,1)
(six,4)
(three,7)
(cluster,1)
(goal-setting,4)
(Oral,1)
(altitude,1)
(noted,1)
(anticipated,1)
(often,3)
(Filipino,1)
(missing,1)
(0-3012.5,1)
(deepens,1)
(﻿Bisphosphonate,1)
(CpG,1)
(blood,4)
(disadvantages,1)
(this,54)
(redox,1)
(molecule,1)
(repeated,1)
(results,30)
(exhibits,2)
(epithelial-mesenchymal,1)
(10.9,2)
(morphological,1)
(5',3)
(differentiated,1)
(plasma,11)
(agreement,1)
(stroma,1)
(METHODS,3)
(T2-T3,1)
(J,1)
(inherited,2)
(consecutive,1)
(Beside,1)
(24,3)
(240,1)
(high-risk,1)
(sequencing,10)
(correlation,7)
(demographics,1)
(capacity,2)
(timing,1)
(promoter,6)
(representing,1)
(Thus,4)
(oral,5)
(4-hydroxybenzylretinone,1)
(accounts,1)
(clinician,1)
(non-synonymous,1)
(MCL-1,1)
(disproportionate,1)
(dinucleotides,1)
(When,2)
(PTMC,3)
(doses,7)
(outcome,8)
(Fine,1)
(Microarrays,1)
(subtype,4)
(drastically,1)
(STAR,2)
(Next-generation,1)
(mutation;,1)
(involves,2)
(Echinococcus,1)
(tissue-conserving,1)
(published,2)
(sampled,1)
(computational,1)
(ER-independent,1)
(appears,1)
(reasonable,1)
(lubrication,2)
(Pd-dppe,2)
(pinch,1)
(BCSCs,3)
(parenchyma,1)
(annexin-V,1)
(high,21)
(Prognosis,1)
(greatly,1)
(currently,5)
(came,1)
(frequencies,1)
(uptake,4)
(metastasis,30)
(787,1)
(abdomen,1)
(one,15)
(recognize,1)
(CI=0.83-2.45,1)
(ungulates,1)
(increased,12)
(185,1)
(Type,1)
(regulation,5)
(endpoints,1)
(eribulin,1)
(Their,4)
(input,5)
(biomarker,5)
(from,52)
(date,4)
(well,14)
(gathered,1)
(homeostasis',1)
(beneficial,2)
(adjacent,3)
(Radiotherapy,1)
(fully,2)
(realistic,2)
(fulvestrant,3)
(summary,2)
(lowest,1)
(Women's,2)
(One,2)
(identification,3)
(last,1)
(xenograft,2)
(display,4)
(effectiveness,1)
(forming,1)
(Twenty-six,1)
(trial,3)
(Collection,1)
(precision,1)
(vitamin,6)
(CCL2,2)
(sibling,1)
(spheroid,2)
(mutations,8)
(contributing,1)
(views,1)
(reproducible,1)
(vimentin,1)
(encountered,1)
(miRNAs,2)
(representations,1)
(variants,5)
(degradation,2)
(enhance,2)
(excision,1)
(cases ≥ G2;,1)
(MBC,11)
(genes,18)
(regarded,1)
(B,1)
(presentation,5)
(screening,13)
(organs,3)
(15-3,2)
(BACKGROUND,4)
(immunoprecipitation,1)
(modulating,1)
(reliable,1)
(Her2+,1)
(components,6)
(we,43)
(measured,5)
(highlighting,1)
(activation,3)
(however,4)
(bioinformatic,2)
(With,1)
(intricately,1)
(magnetization,1)
(Triple,1)
(contrast,12)
(late,12)
(Metastases,1)
(Data,1)
(complexes,8)
(28,1)
(dimers,1)
(little,3)
(radiosurgery,1)
(suggesting,3)
(rs3803304,2)
(indicating,2)
(out,1)
(invadopodia-mediated,1)
(MEAs,1)
(synergistic,1)
(8-12,1)
(policy,1)
(preliminary,1)
(Pt-dppm,1)
(findings,9)
(tumorigenicity,2)
(sustained,1)
(recombinant,1)
(profiling,1)
(immunotherapy-based,1)
(sought,4)
(monolayers;,1)
(immunohistochemical,1)
(proposed,3)
("all-in-one",1)
(rs2229046,1)
(Agents,1)
(cultured,1)
(owing,1)
(continually,1)
(elevated,1)
(MCF10A,1)
(prediagnosis,1)
(hypothesized,1)
(MnZnS,1)
(flaps,2)
(spectroscopy,2)
(BCS,1)
(is,170)
(10%,1)
(putative,1)
(same,3)
(radiologists,1)
(pallidus,6)
(Sequencing,1)
(States,2)
(percentage,1)
(classification,1)
(ROS,2)
(sufficient,1)
(three-dimensional,1)
(saturation,2)
(escalated,1)
(tertiary,1)
(phenomenological,1)
(heritable,1)
(Median,4)
(39,1)
(regimens,4)
(Although,8)
(mechanisms,12)
(Mammography,2)
(in-vitro,1)
(world,1)
(DDSM,1)
(us,1)
(Colorectal,1)
(nuclease,1)
(operational,1)
(partially,1)
(acromegaly,1)
(effects,16)
(tumour-related,1)
(discomfort,1)
(Mechanistic,2)
(details,1)
(Hospital,1)
(parameters,8)
(20-mcg,1)
(Graham,1)
(nanoparticle,2)
(framework,1)
(locoregional,2)
(replicates,1)
(tumorous,1)
(347,1)
(quite,1)
(meters,1)
(composition,2)
(Three,1)
(technologies,1)
(downstream,1)
(consultations,1)
(mainly,3)
(S9,1)
(experienced,1)
(colony,1)
(themselves,1)
(desired,1)
(electron,1)
(recapitulating,1)
(until,1)
(RNAs,2)
(substantial,2)
(member,2)
(burden,3)
(acetylcholine,1)
(although,1)
(Chemical,1)
(optimal,3)
(JQ1,1)
(tumor-to-background,1)
(ineffective,1)
(MUC1,2)
(particularly,1)
(post-injection,1)
(essential,2)
(Lung,1)
(neurological,1)
(node,4)
(test,3)
([the,1)
(binds,1)
(60,2)
(37.5%,1)
(advanced,13)
(32.1,1)
(cytometry,2)
(fidelity,1)
(potent,6)
(liver,4)
(unexplored,1)
(Insulin,1)
(active,2)
(done,1)
(Results,5)
(lag,1)
(581,1)
(CA,1)
(satisfied,1)
(196,1)
(preclinical,1)
(HDAC,1)
(0.0015,1)
(fraction,2)
(VEGF,2)
(controlled,1)
(152,1)
(implemented,2)
(novo,1)
(V,1)
(downregulating,2)
(mycoplasma,1)
(restore,2)
(Together,1)
(WMS-R,4)
(score,1)
(2231,1)
(hallmark,1)
(assessing,2)
(doseRDfor,1)
(experience,2)
(locus,1)
(5.23,1)
(protected,2)
(145,1)
(brain,2)
(mammography,8)
(curability,1)
(impeded,1)
(data,19)
(attitude,1)
(sexual,8)
(priorities,1)
(specific,10)
(comparable,1)
(silencing,7)
(breasts,2)
(2004,3)
(trastuzumab,3)
(populations,4)
(destruction,1)
(inhibited,6)
(31.12.2014,1)
(increase,11)
(gene-expression-based,2)
(Insurance,1)
(nuclear,4)
(able,4)
(CDK,1)
(numbers,1)
([95%,3)
(median,5)
(role,8)
(stage,21)
(thorough,1)
(AC,10)
(near-infrared,2)
(purposively,1)
(because,3)
(assays,5)
(sensitive,5)
(urinary,1)
(useful,4)
(IRs,4)
(TUBO,1)
(confidence,7)
(intrauterine,1)
(inferior,1)
(component;,1)
(important,7)
(low-dose,6)
(gel,1)
(genotypic,1)
(two-pass,1)
(antigen,4)
(propose,2)
(misdiagnosis,1)
(desolvation,1)
(clearly,1)
(9.7,1)
(identifiable,1)
(calculated,2)
(beliefs,3)
(pain,5)
(Scale,1)
(filled,1)
(type,13)
(synergistically,3)
(isolation,1)
(HER2+,4)
(third-degree,2)
(responses,2)
(ionic,1)
(woman's,1)
(make,3)
(implementation,1)
(vitro,8)
(13,2)
(western,3)
(gained,1)
(presented,6)
(dosesLevel,1)
(socioeconomic,1)
(Methods,1)
(prompting,1)
(origin,1)
(2015,1)
(SOX2,1)
(focusing,4)
(nervous,3)
(cognitive,1)
(times,2)
(nationwide,2)
(hazard,10)
(mice,5)
(toxin,1)
(sulfide,1)
(superoxide,2)
(segmentation,1)
(caspase-3,1)
(values,3)
(TNRC9,1)
(0.91,1)
(Agreement,1)
(dismal,1)
(clinicians',1)
(status,7)
(Fanconi,1)
(G1,2)
(originally,2)
(30230,1)
(MCF-7,11)
(no-radiotherapy,1)
(extracts,1)
(transcription,5)
(syndromes,1)
(mTOR,1)
(Survival,1)
(ultimately,1)
(even,5)
(1.27,1)
(0.950,1)
(differentiate,1)
(0.88-0.99;,1)
(ovarian,6)
(0.015,1)
(flow,2)
(extent,3)
(ligases,1)
(ability,4)
(contamination,1)
(colorectal,3)
(shows,1)
(cavity,1)
(contralateral,2)
(cell‑surface,1)
(We,39)
(responsible,4)
(profiles,5)
(basal/HER2+,4)
(primary,18)
(54%,1)
(Culture,1)
(directly,1)
(rising,2)
(now,3)
(has,30)
(four,6)
(Stage,1)
(set,1)
(n = 25,2)
(z,1)
(specificities,1)
(University,1)
(body,5)
(via,9)
(upregulated,3)
(azoospermia,1)
(regulators,2)
(LABC,2)
(As,4)
(8/18,1)
(requires,2)
(deposition,1)
(5 ,1)
(examinations,1)
(extracellular,2)
(associations,1)
(17,1)
(2-dimensional,1)
(EXTL1,1)
(knowledge,4)
(fibronectin;,1)
(initiates,1)
(controls,2)
(lesion,5)
(historical,1)
(EDPs,2)
(means,2)
(rs11555431,1)
(NMD3,1)
(clarify,1)
(formulation,2)
(0.87-1.73;,1)
(cell,66)
(relapsed,3)
(patients,136)
(helps,2)
(hair,1)
(Oncolytic,2)
(coactivators,1)
(Pik3caH1047R-induced,1)
(Lamiaceae,1)
(hypermethylation,3)
(static,1)
(person-years,3)
(isoforms,1)
(SLC3A2,1)
(thesuspicious,1)
(network,2)
(fluorescence,2)
(cardiotoxicity;,1)
(Delayed,2)
(poor,10)
(centers,1)
(T2,1)
(excellent/good,1)
(GSK3β,1)
(1993,1)
(mastectomy,7)
(Flow,1)
(example,1)
(CYP27B1,1)
(QOL,1)
(calculate,2)
(provides,2)
(limited,2)
(CI,7)
(oncolytic,2)
(inheritance,1)
(real,1)
(disappeared,1)
(diffuse,2)
(QPCR,1)
(Ulm,1)
(Verbal,1)
(BP-treated,2)
(Patients,5)
(whereby,2)
(measure,1)
(potential,16)
(resonance,3)
(selecting,1)
(reproducibility,1)
(Display,1)
(aberrations,1)
(time-to-death,2)
(study;,2)
(11-bisdiphenylphosphinomethane,1)
(agents,8)
(antibodies,1)
(collect,2)
(saccharinate,1)
(PR,3)
(therapeutic,18)
(HER3,3)
(start,1)
(6,2)
(thyroidectomy,1)
(NF-κB/SOX4,1)
(clinicopathological,2)
(T-PAT,5)
(Cosmesis,1)
(women,53)
(searches,1)
(shrinkage,2)
(anticancer,9)
(reduced,7)
(antagonist,2)
(hospital,2)
(interest,2)
(monoclonal,2)
(detected,5)
(Set,1)
(Index,3)
(specifically,1)
(2800,1)
(antiproliferative,2)
(consistent,3)
(0.98-1.62;,1)
(325,1)
(Nuclear,1)
(will,11)
(restored,1)
(National,2)
(widespread,1)
(radical,4)
(Multi-scale,1)
(subset,2)
(stratification,3)
(very,13)
(decreased,4)
(advance,1)
(Audio,1)
(adjusted,1)
(realistically,1)
(HR,11)
(aldehyde,1)
(follows,1)
(prognosis,18)
(metastases,14)
(ERBB3,4)
(ER + tumors,1)
(reduce,4)
(models,11)
(reviewers,1)
(ER+,7)
(arise,1)
(Taxol®,2)
(2008,1)
(powers,1)
(index,6)
(concentrations,2)
(approaches,10)
(occult,1)
(costs,2)
(past,2)
(YBCS',1)
(acceptable,1)
(poisoning,1)
(BIM,1)
(lung,10)
(cytokine,2)
(46,1)
(invadopodial,1)
(papillary,1)
(imagesneed,1)
(treatment-related,1)
(activity-guided,1)
(Aviv,1)
(This,31)
(7%,2)
(who,17)
(87%,1)
(enhanced,2)
(prognoses,1)
(Adenoid,1)
(adverse,1)
(0.04,1)
(targets,2)
(years,26)
(5.8%,1)
(Anthracyclines,1)
(tissues,11)
(invariance,1)
(homologous,4)
(motivation,1)
(positivity,1)
(administration,2)
(ERK,1)
(mg/m2,2)
(ZK-75-1,1)
(article,3)
(Nevertheless,1)
(build,1)
(when,9)
(recurrent,6)
(eg,1)
(glycosyltransferase,1)
(as,92)
(medicine,1)
(purpose,3)
(signaling,14)
(light,1)
(survival,32)
(together,2)
(cosmesis,2)
(BCs,1)
(apoptosis,17)
(participated,1)
(leading,20)
(optimizing,1)
(insulin,3)
(progression-free,4)
(efficacies,1)
(independent,4)
(cytology,1)
(transcriptomes,1)
(5.2;,1)
(sizes,1)
(issues,3)
(versus,4)
(masses,1)
(reticulum,1)
(Locoregional,1)
(Limited,1)
(signalling,2)
(Fluorescence,1)
(chart,2)
(summarizes,1)
(ZJU-0725,3)
(R,1)
(impact,7)
(allelic,3)
(tumorigenesis,3)
(cellular,4)
(TBC1D10A,1)
(males,2)
(buccal,1)
(cytotoxic,3)
(individuals,1)
(degrade,1)
(BP,3)
(overheating,1)
(brachytherapy,1)
(causes,1)
(gives,1)
(shift,1)
(volume,1)
(Cell,2)
(Bioinformatic,1)
(expressing,1)
(neutropenia,1)
(mesylateERIhas,1)
(90%,3)
(reversed,1)
(excellent,2)
(safety,4)
(c-MET,1)
(men,1)
(areas,2)
(p53,1)
(prior,7)
(according,6)
(sinus,1)
(35,1)
(migration,4)
(26.5%,1)
(generating,2)
(lethality,1)
(marker,3)
(attenuation,1)
(indicates,1)
(air,1)
(accumulated,2)
(Sexual,2)
(CCDC137,1)
(biopsy,6)
(rim,1)
(diagnosed,22)
(desire,2)
(five,6)
(51.1%,1)
(decrease,1)
(breast-conserving,3)
(BMI,2)
(substrates,1)
(osteopontin-based,2)
(differences,4)
(rs13281615,1)
(June,1)
(melanoma,2)
(12.4%,1)
(excitation,2)
(nine,2)
(2002-2014,1)
(cell-like,1)
(ultrasound-guided,1)
(documentation,1)
(relapse,2)
(easy,2)
(4.8,1)
(﻿The,2)
(man,1)
(fibroglandular,1)
(difficult,2)
(deacetylase,1)
(unknown,3)
(peptides,3)
(vary,1)
(3.5,1)
(conserving,1)
(39-year-old,1)
(non-functioning,1)
(Six,2)
(coefficients,2)
(coregulators,1)
(MCF‑7,1)
(Barrett's,1)
(tissue;,1)
(Unfortunately,1)
(communication,1)
(usual,1)
(prognostic,19)
(mucosa,1)
(numerous,2)
(since,1)
(seem,1)
(efficiently,1)
(∼50%,1)
(ECOG,3)
(so-called,2)
(64.6,1)
(pollution,1)
(However,16)
(supported,1)
(utilized,1)
(validated,5)
(interaction,2)
(chronic,1)
(larynx,1)
(plagued,1)
(undergoing,5)
(processed,1)
(pathway,17)
(53,1)
(endocrine-independent,1)
(Invadopodia,1)
(nontarget,2)
(with,254)
(January,2)
(2,16)
(intraclass,1)
(DNA/HSA,1)
(1.1mg/m2,1)
(Women,1)
(smoking-related,2)
(dysfunction,5)
(BRCA,1)
(explained,2)
(nonstandardized,1)
(tumor-suppressor,1)
(investigation,8)
(adaptive,2)
(Neurological,1)
(proportion,2)
(options,4)
(Subread,1)
(Genotypes,1)
(background,1)
(culture,2)
(Shearlet,4)
(64-year-old,1)
(cycle,7)
(elastotic,1)
(doubling,1)
(radiotherapy,19)
(understand,4)
(their,26)
(rare,11)
(IL-1�,2)
(receptors-ERα66,1)
(preferentially,2)
(valuable,2)
(exostosin,1)
(get,1)
(sulforhodamine,1)
(degummed,1)
(IKBKE,1)
(50.6%,2)
(possess,1)
(providing,1)
(Mechanisms,1)
(anthracyclines,3)
(wall,5)
(assembly,1)
(reprogramming,1)
(directional,1)
(length,1)
(undetectable,1)
(alpha,3)
(61.6%,1)
(NGS,1)
(decline,2)
(﻿To,3)
(radiation;,1)
